BeOne Medicines (BEIGF) Common Equity (2015 - 2026)

BeOne Medicines (BEIGF) has reported Common Equity for 12 consecutive years, with $5.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 37.22% year-over-year to $5.2 billion in Q2 2026; TTM through Jun 2026 was $5.2 billion, a 37.22% increase from a year earlier, with the FY2025 full-year figure at $4.4 billion, up 30.88% from the prior year.
• Common Equity was $5.2 billion for Q2 2026 at BeOne Medicines, up from $4.8 billion in the prior quarter.
• Over five years, Common Equity peaked at $5.8 billion in Q1 2022 and troughed at $3.3 billion in Q4 2024.
• A 5-year average of $4.1 billion and a median of $4.0 billion in 2023 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 44.22% in 2022, down 28.52% in 2022.
• Over 5 years, Common Equity stood at $4.4 billion in 2022, then declined by 19.3% to $3.5 billion in 2023, then slipped by 5.8% to $3.3 billion in 2024, then surged by 30.88% to $4.4 billion in 2025, then rose by 18.64% to $5.2 billion in 2026.
• The last three Common Equity figures came in at $5.2 billion (Q2 2026), $4.8 billion (Q1 2026), and $4.4 billion (Q4 2025), per Business Quant data.